TRANSLATIONAL RELEVANCE:
Currently, there are no clinically employed markers to define patients that will benefit from neoadjuvant chemotherapy. Here an unbiased systematic approach was used to define pathways and specific markers associated with the response to neoadjuvant chemotherapy in breast cancer. These analyses revealed that genes involved in cell cycle control processes that are regulated by the RB/E2F pathway are significantly associated with response to chemotherapy in both ER-positive and ER-negative breast cancer. However, additional genes were identified that were predictive of response, particularly across different therapeutic regimens. Importantly, identified genes associated with pathological complete response or residual disease were evaluated in independent cohorts by gene expression and immunohistochemistry demonstrated strong predictive power. Together these data suggest that a relatively small number of biomarkers can be identified to predict response to neoadjuvant chemotherapy.
INTRODUCTION:
While breast cancer is treated with a variety of targeted agents, conventional cytotoxic chemotherapy remains a mainstay of therapy (1-4). At present, complex chemotherapy regimens are applied in multiple distinct clinical scenarios in the treatment of breast cancer. It is well appreciated that triple negative breast cancer is treated largely exclusively with chemotherapy (2, 5, 6) ; however, other forms of breast cancer are also treated with chemotherapy.
For example, luminal B breast cancer is often treated with adjuvant chemotherapy in conjunction with ER targeted therapeutics (7) (8) (9) (10) . Similarly, Her2 positive cancers are treated with Trastuzumab in conjunction with taxane based chemotherapy (11) . In all of these contexts it is critically important to elucidate determinants of the response to chemotherapy.
One means to evaluate the response to chemotherapy in clinical specimens involves the analyses of the response to neoadjuvant chemotherapy (2, 12, 13) . While historically surgery has preceded treatment with adjuvant therapy, there has been a significant increase in neoadjuvant therapy (18, 19) . Studies have shown that the response to neoadjuvant therapy is effective at predicting the ultimate course of tumor behavior and specific determinants of that response are being sought (2, 12, 14, 15) . Importantly, pathological response in neoadjuvant studies reveals tumor response to a given therapy independent of other prognostic features of disease, and therefore markers defined in the analyses of neoadjuvant treatment could be inferred to portend activity in the adjuvant setting as well.
Several studies have analyzed the gene expression programs associated with response to neoadjuvant chemotherapy (14) (15) (16) (17) (18) . Our group and others have analyzed specific gene expression programs associated with response to chemotherapy. These studies have indicated that gene expression programs involved in RB/E2F biology or proliferation associated properties are associated with pathological complete response (17) (18) (19) (20) . In contrast, others have used data 5 sets to infer predictive markers using supervised computational approaches (14, 15, 21, 22) .
Here we sought to use a simple method to identify individually predictive genes that can be used singly or in combination across chemotherapy regimens and disease subtypes that could be used to direct therapy. These small number of genes returned by such a method can be individually analyzed by immunohistochemistry or other methods that are readily amenable to clinical utilization.
MATERIALS AND METHODS

Datasets:
Raw .CEL files and platform annotations for gene expression datasets GSE20194, GSE20271, GSE22093, GSE23988, and GSE25066, GSE41998, GSE2226 were downloaded from the Gene Expression Omnibus (GEO). A comprehensive summary of the cohorts and related citations are provided in the supplemental data (Supplemental Table 4 ). Datasets were normalized by the robust multiarray average algorithm (RMA) from limma Bioconductor packages in R. We assumed that the probes annotation supplied by the array manufacturer were accurate. For genes with multiple probe sets, we averaged the gene expression levels.
Patients without response information will be excluded from analysis. We pooled the neoadjuvant patients from the GEO datasets GSE20194, GSE20271, GSE22093, GSE23988, and GSE25066 to develop the "NEO" dataset. The datasets GSE41998 and GSE2226 were employed for independent validation (Supplemental Table 4 ).
ROC screening:
The area under receiver operator characteristic curve (AUC) was used to screen the genes according to their ability to distinguish between two phenotypes, and the AUC was calculated by R-package ROCR. We ran ROCR for all the genes in the microarray from different treatment types (TA, TFAC and FAC), different subtypes (ER-/+) and pooled NEO dataset. We ranked genes from different categories based on the patients who either had a complete response (pCR) or retained residual disease (RD) after chemotherapy. The ranking of the genes was performed for genes predictive of prognosis. (Figure 1 ). This analysis provided a rank ordering of individual genes associated with response ( Figure 1A ).
The top 20 predictive AUC values were comparable between the two data sets (0.73-0.79 vs.
0.75-0.81). Interestingly, although the TFAC and TA datasets are independent, the same gene, the nuclear oncogene DEK, was found to have the top predictive power ( Figure 1A ). Gene ontology analysis of the top 150 genes by AUC ranking demonstrated that in both TA and TFAC there was a significant over-representation of genes associated with cell cycle ( Figure 1B) .
Notably, many of these genes are regulated by the RB/E2F pathway that has been independently associated with response to neoadjuvant chemotherapy (24, 25) . Consistent with these findings, analysis of multiple signatures associated with cell cycle genes including the GGI signature (26), the CIN70 signature (27) , the OncotypeDx proliferation genes (28), Mammaprint ( Figure 1C ). Additionally, each signature had potent ROC characteristics in the datasets ( Figure   1D ). Thus, these findings reinforce the concept that cell cycle regulated genes can have profound influence related to the response to neoadjuvant chemotherapy in breast cancer. Figure 2C ). In contrast, TTK was highly predictive in TA and TFAC but not FAC ( Figure 2D ). These data suggest that it may be particularly challenging to define biomarkers of response that would be useful across multiple manifestations of disease subtypes and treatment approaches.
Distinct
Identification of genes that are predictive of response to chemotherapy in both ERpositive and ER-negative breast cancer: While both ER-positive and ER-negative breast cancers are treated with similar chemotherapy regimens in the neoadjuvant setting, there is clearly a distinction in the relative response between these two forms of disease (6, 20, 31) .
Therefore, we initially evaluated determinants that may be specific for ER-positive vs. ERnegative breast cancer. To this end, we combined all treatment groups to build a large single data set (Supplemental Table 1 Top performing predictive makers retain predictive value in independent validation cohorts with distinct therapeutic regimens: The analysis performed supported the potential utilization of a small set of 9 markers for the prediction of therapeutic response. To validate the performance two additional cohorts were utilized, wherein patients were treated with AC and taxane or the microtubule poison ixabepilone or AC with or without taxane (Summarized in Supplemental Table 2 ). In these cohorts, the 9 genes identified were appropriately associated with pCR and RD as determined in the discovery cohorts ( Figure 5A ). Importantly the genes in these validation cohorts exhibited potent predictive value in tertile analysis and ROC analysis comparable to that observed in the discovery cohorts ( Figure 5B and 5C) . Thus, the small panel of genes defined in this fashion could have utility in generally predicting therapeutic response.
Immunohistochemical validation of the robust predictive value of DEK and BCAM in an additional neoadjuvant cohort: While molecular approaches are being progressively employed in clinical care, immunohistochemistry remains the mainstay of breast cancer biomarker analysis to guide treatment (e.g. ER-staining).
Therefore, we optimized immunohistochemical staining of the two top performing markers, DEK and BCAM. DEK stains nuclei and exhibited a range of staining from negative to high staining in 100% of cells ( Figure   6A ). To quantify the staining a modified histo-score was utilized where the intensity (0-3) was multiplied against the percent of cells staining positive divided into quartile groups. This approach yielded a range of products from 0 to 12 that were employed in tertiles and as a 
"semi-continuous" variable.
BCAM exhibits membrane staining and the percent of cells exhibiting robust membrane staining was utilized both with tertile cutpoints, and as a continuous variable.
These marker levels were evaluated by ROC analysis (Supplemental Figure S5 ).
These data demonstrated potent predictive value of both markers. Using defined tertile 
DISCUSSION:
The improved treatment of cancer is tied to a more targeted approach to therapy. Typically, this is viewed in the context of drugs that have a specific molecular target; however, one of the most important areas in clinical care is to improve the delivery of chemotherapy. Across breast cancer subtypes chemotherapy is routinely utilized to reduce the burden of disease in the neoadjuvant setting, or prevent disease recurrence in the adjuvant setting (2, 12) .
Chemotherapy can provide long-term clinical benefit in breast cancer, as patients with tumors that experience a complete pathological response to neoadjuvant chemotherapy have a particularly good long-term prognosis (7). This finding is highly relevant in the area of triple negative breast cancer, wherein a pathological complete response denotes the same prognosis as patients with ER-positive breast cancer (7) . In contrast, tumors that progress while undergoing neoadjuvant chemotherapy have a poor prognosis, and are generally resistant to chemotherapy. For these reasons, it would be ideal to have a means to predict response to chemotherapy. This would allow chemotherapy to be targeted to patients whose tumors are most likely to benefit from such treatment, and consider surgery in combination with other modalities for patients that would be predicted to have an unfavorable response to treatment.
The primary objective of neoadjuvant chemotherapy is to improve surgical outcomes, and as with any systemic chemotherapy, it is used to reduce risk of distant recurrence. In principle, any tumor that is a candidate for adjuvant systemic chemotherapy could be treated with neoadjuvant chemotherapy. In breast cancer, the use of systemic adjuvant chemotherapy is largely evaluated based on disease subtype. For example, triple negative breast cancers will almost universally receive chemotherapy, while for ER-positive breast cancer the use of molecular signatures (e.g. PAM50, Mammaprint or OncotypeDx) are used to evaluate the benefit from adjuvant chemotherapy beyond endocrine therapy alone (28, (32) (33) (34) (35) . Here we identified genes that had high-predictive value in ER-positive and ER-negative cohorts. Due to the frequent use of Herceptin in Her2-positive breast cancer, those cases were excluded from the analysis.
In the consideration of ER-positive breast cancer, as may be expected proliferation associated genes were associated with therapeutic response since these genes differentiate luminal A and luminal B subtypes. In general, all proliferation signatures tested (ie.
GGI, Oncotype, CIN, RB-signature) had similar activity in predicting response, although the RBsignature had marginally better performance characteristics. Interestingly, such proliferation gene signatures were also effective within ER-negative breast cancer and individual proliferation genes harbored the top AUC. Unexpectedly, the individual genes associated with response were largely distinct from those in ER-positive disease. Genes involved in mitosis (e.g. Cyclin B2, MAD2L1, UBE2C) represented top ER-positive genes, while genes involved in DNA replication and DNA repair (MCM3, MSH2, FANCL) were most predictive in ER-negative breast cancer. Interspersed within the dominant cell cycle/proliferation associated gene programs were genes that have been implicated in the response to chemotherapy. For example, LDHB has been recently reported as a determinant of chemotherapy response and was identified herein (36) . In spite of the overall similarity of gene function, investigating the intersection between ER-positive and ER-negative revealed a small number of genes which maintained robust predictive power and suggested that a "general" set of markers could be identified that would be actionable within either the ER-positive or ER-negative subtypes. Interestingly, this cadre of genes was considerably over-represented for association with pCR that was reflective of the fact that the vast majority of the top predictive genes in ER-negative breast cancer are associated with pCR not RD.
Most chemotherapy used in the neoadjuvant setting represents an anthracycline in combination with a taxane (TA), cytoxan (AC), or both (ACT) (2, 12, 37) . In the cohorts employed herein, there was a significant difference in the top predictive markers between the TA and TFAC cohorts vs. the FAC cohort. At present it is impossible to determine if this is a specific feature of the therapy utilized or represents some form of technical bias within the independent cohorts. However, the data from these analyses reinforces the concept that investigating multiple cohorts and treatments is important, and defining markers that are predictive under multiple independent contexts are presumptively critical for delineating utility under clinical conditions that may be "less than ideal". For example, the interrogation of genes specific to the FAC cohort would yield many genes that have limited predictive power in other contexts (e.g. IFI16). In the analysis of the intersection between treatment groups we defined only 9 genes that were effective in all treatment settings. Importantly we defined genes that were associated with cell cycle and pCR (e.g. DEK and DONSON) as well as genes associated with RD (e.g BCAM and METRN). DEK is a nuclear oncogene that is implicated in DNA damage repair and apoptosis (38) . LBR is the lamin B receptor, while YEATS2 and DONSON have largely unknown functions in mammalian cells. Of these genes only a subset are cell cycle regulated (LBR, DONSON, and DEK); therefore, the inclusion of the other genes ostensibly provides complementary biological information that would be expected to improve performance. Interestingly, none of these genes have been identified as being particularly relevant markers for the response to neoadjuvant chemotherapy. However, in our additional validation cohorts these markers continued to be predictive of chemotherapy response. These findings contrasted with the analyses of Theraprint (Agendia Inc.) that has been presented as a means to judge potential response to chemotherapy.
The Theraprint genes, and similar targeted panels, are based on individual studies of single genes and functional associations between proteins and drugs. An example, is that the levels of ribonucleotide reductase will infer response to anti-metabolites. We evaluated all genes within Theraprint individually and found that very few of these genes harbored significant predictive power (Supplemental Figure   6 ). In this setting ESR1 (estrogen receptor) was the most potent predictive marker. These findings could represent the fact that neoadjuvant chemotherapy is not delivered as a single agent; or more likely, that due to the complexity of cancer simple gene inferences based on functional data do not uniformly hold true. 
